Boris Rudic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3484950/publications.pdf

Version: 2024-02-01

430874 501196 45 908 18 28 h-index citations g-index papers 47 47 47 1247 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	Early repolarization pattern is associated with ventricular fibrillation in patients with acute myocardial infarction. Heart Rhythm, 2012, 9, 1295-1300.	0.7	83
2	Efficacy and survival in patients with cardiac contractility modulation: Long-term single center experience in 81 patients. International Journal of Cardiology, 2015, 183, 76-81.	1.7	75
3	Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide. Heart Rhythm, 2012, 9, 776-781.	0.7	52
4	Subcutaneous implantable cardioverter-defibrillator: First single-center experience with other cardiac implantable electronic devices. Heart Rhythm, 2015, 12, 2230-2238.	0.7	48
5	Short QT Syndrome – Review of Diagnosis and Treatment. Arrhythmia and Electrophysiology Review, 2014, 3, 76.	2.4	42
6	Brugada syndrome: clinical presentation and genotypeâ€"correlation with magnetic resonance imaging parameters. Europace, 2016, 18, 1411-1419.	1.7	40
7	Longâ€Term Followâ€Up of Patients With Short QT Syndrome: Clinical Profile and Outcome. Journal of the American Heart Association, 2018, 7, e010073.	3.7	35
8	Hypothermia-Induced Loss of Endothelial Barrier Function Is Restored after Dopamine Pretreatment: Role of p42/p44 Activation. Transplantation, 2006, 82, 534-542.	1.0	33
9	SCN5A mutations in 442 neonates and children: genotype–phenotype correlation and identification of higher-risk subgroups. European Heart Journal, 2018, 39, 2879-2887.	2.2	33
10	A cellular model of Brugada syndrome with SCN10A variants using human-induced pluripotent stem cell-derived cardiomyocytes. Europace, 2019, 21, 1410-1421.	1.7	33
11	Simultaneous Nonâ€Invasive Epicardial and Endocardial Mapping in Patients With Brugada Syndrome: New Insights Into Arrhythmia Mechanisms. Journal of the American Heart Association, 2016, 5, .	3.7	32
12	Cardiac contractility modulation: first experience in heart failure patients with reduced ejection fraction and permanent atrial fibrillation. Europace, 2014, 16, 1205-1209.	1.7	29
13	PQ segment depression in patients with short QT syndrome: A novel marker for diagnosing short QT syndrome?. Heart Rhythm, 2014, 11, 1024-1030.	0.7	28
14	Hyperthermia Influences the Effects of Sodium Channel Blocking Drugs in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. PLoS ONE, 2016, 11, e0166143.	2. 5	28
15	Low Prevalence of Inappropriate Shocks in Patients With Inherited Arrhythmia Syndromes With the Subcutaneous Implantable Defibrillator Single Center Experience and Longâ€Term Followâ€Up. Journal of the American Heart Association, 2017, 6, .	3.7	25
16	Recommendations regarding cardiac stereotactic body radiotherapy for treatment refractory ventricular tachycardia. Heart Rhythm, 2021, 18, 2137-2145.	0.7	25
17	Defibrillation failure in patients undergoing replacement of subcutaneous defibrillator pulse generator. Heart Rhythm, 2020, 17, 455-459.	0.7	24
18	Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting. BMC Cardiovascular Disorders, 2018, 18, 52.	1.7	20

#	Article	IF	CITATIONS
19	Long-term follow-up of implantable cardioverter-defibrillators in Short QT syndrome. Clinical Research in Cardiology, 2019, 108, 1140-1146.	3.3	20
20	Incremental benefit of late gadolinium cardiac magnetic resonance imaging for risk stratification in patients with hypertrophic cardiomyopathy. Scientific Reports, 2017, 7, 6336.	3.3	19
21	Early repolarization pattern: a marker of increased risk in patients with catecholaminergic polymorphic ventricular tachycardia. Europace, 2016, 18, 1587-1592.	1.7	16
22	Longâ€term results of combined cardiac contractility modulation and subcutaneous defibrillator therapy in patients with heart failure and reduced ejection fraction. Clinical Cardiology, 2018, 41, 518-524.	1.8	15
23	Right Ventricular and Right Atrial Involvement Can Predict Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy?. International Journal of Medical Sciences, 2016, 13, 1-7.	2.5	14
24	Incidence, mechanisms, and clinical impact of inappropriate shocks in patients with a subcutaneous defibrillator. Europace, 2020, 22, 761-768.	1.7	14
25	Comparison of transvenous vs subcutaneous defibrillator therapy in patients with cardiac arrhythmia syndromes and genetic cardiomyopathies. International Journal of Cardiology, 2021, 323, 100-105.	1.7	13
26	Mitral annular plane systolic excursion is an easy tool for fibrosis detection by late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Archives of Cardiovascular Diseases, 2015, 108, 356-366.	1.6	11
27	Reduced Na ⁺ Current in Native Cardiomyocytes of a Brugada Syndrome Patient Associated With β-2-Syntrophin Mutation. Circulation Genomic and Precision Medicine, 2018, 11, e002263.	3.6	11
28	Systematic ajmaline challenge in patients with long QT 3 syndrome caused by the most common mutation: a multicentre study. Europace, 2017, 19, 1723-1729.	1.7	10
29	Interaction between CIEDs and modern radiotherapy techniques: Flattening filter free-VMAT, dose-rate effects, scatter radiation, and neutron-generating energies. Radiotherapy and Oncology, 2020, 152, 196-202.	0.6	10
30	Cardiac Contractility Modulation in Patients with Ischemic versus Non-ischemic Cardiomyopathy: Results from the MAINTAINED Observational Study. International Journal of Cardiology, 2021, 342, 49-55.	1.7	10
31	Hypothermic Preservation Up-Regulates Calpain Expression and Increases Ubiquitination in Cultured Vascular Endothelial Cells: Influence of Dopamine Pretreatment. Journal of Surgical Research, 2010, 160, 325-332.	1.6	8
32	Cardiac impact of R-wave triggered irreversible electroporation therapy. Heart Rhythm, 2018, 15, 1872-1879.	0.7	7
33	Extent of Late Gadolinium Enhancement Predicts Thromboembolic Events in Patients With Hypertrophic Cardiomyopathy. Circulation Journal, 2020, 84, 754-762.	1.6	7
34	Risk stratification of patients with Brugada syndrome: the impact of myocardial strain analysis using cardiac magnetic resonance feature tracking. Hellenic Journal of Cardiology, 2021, 62, 329-338.	1.0	6
35	Prediction of cardiac events with nonâ€contrast magnetic resonance feature tracking in patients with ischaemic cardiomyopathy. ESC Heart Failure, 2021, , .	3.1	6
36	Extent of peri-infarct scar on late gadolinium enhancement cardiac magnetic resonance imaging and outcome in patients with ischemic cardiomyopathy. Heart Rhythm, 2021, 18, 954-961.	0.7	5

#	Article	IF	CITATIONS
37	Impact of baseline left ventricular ejection fraction on longâ€term outcomes in cardiac contractility modulation therapy. PACE - Pacing and Clinical Electrophysiology, 2022, 45, 639-648.	1.2	5
38	The use of noninvasive ECG imaging for examination of a patient with Brugada syndrome. HeartRhythm Case Reports, 2015, 1, 260-263.	0.4	4
39	Mid-regional pro-adrenomedullin and N-terminal pro B-type natriuretic peptide predict the recurrence of atrial fibrillation after cryoballoon pulmonary vein isolation. International Journal of Cardiology, 2016, 203, 369-371.	1.7	4
40	Clinical Profile and Long-Term Follow-Up of Children with Brugada Syndrome. Pediatric Cardiology, 2020, 41, 290-296.	1.3	3
41	Local doseÂrate effects in implantable cardioverter–defibrillators with flattening filter free and flattened photon radiation. Strahlentherapie Und Onkologie, 2022, 198, 566-572.	2.0	3
42	Reply to the Editorâ€"PQ-Segment Depression in Short QT Syndrome Patients: A Novel Marker for Diagnosing Short QT Syndrome?. Heart Rhythm, 2014, 11, e8.	0.7	1
43	A shocking experience: inappropriate subcutaneous implantable cardioverter-defibrillator shock at a public swimming pool. Europace, 2018, 20, 2020-2020.	1.7	1
44	Proarrhythmic Effect of "Reverse Mode Switch―in a Patient with Longâ€QT Syndrome. Journal of Cardiovascular Electrophysiology, 2014, 25, 1133-1134.	1.7	0
45	Cardioprotective Effects of Dronedarone Mediated by the Influence on the Expression of Urokinase-Type Plasminogen Activator Receptor. Journal of Vascular Research, 2019, 56, 92-96.	1.4	0